 Rama Kant
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chemical Warfare Agents | 12 | 2025 | 89 | 2.690 |
Why?
| | Mustard Gas | 6 | 2025 | 77 | 2.230 |
Why?
| | Corneal Injuries | 9 | 2024 | 42 | 2.170 |
Why?
| | Dexamethasone | 6 | 2025 | 366 | 1.170 |
Why?
| | Cornea | 11 | 2024 | 154 | 1.150 |
Why?
| | Anti-Inflammatory Agents | 3 | 2025 | 478 | 0.910 |
Why?
| | Limbus Corneae | 1 | 2025 | 8 | 0.880 |
Why?
| | Rabbits | 14 | 2025 | 651 | 0.840 |
Why?
| | Mechlorethamine | 7 | 2024 | 52 | 0.830 |
Why?
| | Arsenicals | 4 | 2023 | 28 | 0.640 |
Why?
| | Stem Cells | 1 | 2025 | 626 | 0.630 |
Why?
| | Epithelium, Corneal | 4 | 2020 | 41 | 0.450 |
Why?
| | Prostatic Neoplasms | 4 | 2026 | 978 | 0.450 |
Why?
| | Naproxen | 2 | 2026 | 21 | 0.440 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2026 | 344 | 0.350 |
Why?
| | Aspirin | 2 | 2026 | 407 | 0.350 |
Why?
| | Oxidative Stress | 4 | 2025 | 1350 | 0.330 |
Why?
| | Hydrocarbons, Chlorinated | 2 | 2021 | 23 | 0.320 |
Why?
| | Irritants | 5 | 2024 | 42 | 0.310 |
Why?
| | Corneal Neovascularization | 3 | 2017 | 15 | 0.270 |
Why?
| | Animals | 23 | 2026 | 38141 | 0.260 |
Why?
| | Carcinogenesis | 3 | 2024 | 227 | 0.260 |
Why?
| | Transcriptional Regulator ERG | 2 | 2024 | 14 | 0.250 |
Why?
| | DNA Damage | 4 | 2021 | 434 | 0.250 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2026 | 212 | 0.240 |
Why?
| | Serine Endopeptidases | 2 | 2024 | 129 | 0.240 |
Why?
| | Prostate | 2 | 2024 | 158 | 0.230 |
Why?
| | Inflammation Mediators | 3 | 2024 | 505 | 0.230 |
Why?
| | Chromatography, Liquid | 2 | 2024 | 445 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 153 | 0.210 |
Why?
| | Oncogene Fusion | 1 | 2024 | 11 | 0.210 |
Why?
| | Cyclooxygenase 2 | 6 | 2021 | 166 | 0.200 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 566 | 0.200 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.190 |
Why?
| | Bifidobacterium longum | 1 | 2022 | 6 | 0.190 |
Why?
| | Proteomics | 3 | 2024 | 1191 | 0.190 |
Why?
| | Oryza | 1 | 2022 | 32 | 0.180 |
Why?
| | Inflammation | 5 | 2025 | 2883 | 0.170 |
Why?
| | Actins | 1 | 2024 | 421 | 0.170 |
Why?
| | Eye Burns | 1 | 2021 | 14 | 0.170 |
Why?
| | Matrix Metalloproteinase 9 | 5 | 2021 | 130 | 0.170 |
Why?
| | Burns, Chemical | 1 | 2021 | 33 | 0.170 |
Why?
| | Apoptosis | 5 | 2021 | 2411 | 0.160 |
Why?
| | Corneal Stroma | 2 | 2017 | 24 | 0.150 |
Why?
| | Protein Carbonylation | 1 | 2019 | 57 | 0.150 |
Why?
| | Pesticides | 1 | 2019 | 63 | 0.150 |
Why?
| | Oxygen | 2 | 2021 | 986 | 0.140 |
Why?
| | Protective Agents | 1 | 2017 | 42 | 0.130 |
Why?
| | Phosgene | 1 | 2017 | 5 | 0.130 |
Why?
| | Oximes | 1 | 2017 | 26 | 0.130 |
Why?
| | Neovascularization, Pathologic | 1 | 2018 | 284 | 0.120 |
Why?
| | Skin | 3 | 2017 | 766 | 0.120 |
Why?
| | Eye Injuries | 1 | 2016 | 53 | 0.110 |
Why?
| | Biomarkers | 3 | 2022 | 4283 | 0.110 |
Why?
| | Cell Cycle | 1 | 2018 | 595 | 0.110 |
Why?
| | Skin Diseases | 1 | 2017 | 152 | 0.110 |
Why?
| | Hematopoietic System | 1 | 2014 | 7 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2019 | 550 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 850 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2022 | 923 | 0.110 |
Why?
| | Interleukin-8 | 3 | 2021 | 269 | 0.100 |
Why?
| | Indoles | 1 | 2018 | 508 | 0.100 |
Why?
| | Organ Culture Techniques | 3 | 2021 | 149 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 774 | 0.100 |
Why?
| | Mice | 8 | 2026 | 18338 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1112 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 167 | 0.100 |
Why?
| | Male | 12 | 2026 | 72817 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2015 | 306 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 436 | 0.090 |
Why?
| | Spleen | 1 | 2014 | 511 | 0.090 |
Why?
| | Mice, Hairless | 3 | 2017 | 47 | 0.090 |
Why?
| | Cell Survival | 3 | 2021 | 1094 | 0.080 |
Why?
| | Emulsions | 2 | 2021 | 59 | 0.080 |
Why?
| | Corneal Keratocytes | 2 | 2021 | 8 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 993 | 0.070 |
Why?
| | Blood Vessels | 2 | 2021 | 167 | 0.070 |
Why?
| | Lipid Peroxidation | 2 | 2019 | 163 | 0.060 |
Why?
| | Kidney | 1 | 2014 | 1498 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1953 | 0.060 |
Why?
| | Administration, Cutaneous | 2 | 2017 | 126 | 0.060 |
Why?
| | Cytokines | 2 | 2024 | 2054 | 0.050 |
Why?
| | Oncogene Proteins | 1 | 2024 | 61 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2019 | 1710 | 0.050 |
Why?
| | Unfolded Protein Response | 1 | 2023 | 58 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 536 | 0.050 |
Why?
| | Neoplasms, Experimental | 1 | 2024 | 168 | 0.050 |
Why?
| | Phosphorylation | 2 | 2019 | 1707 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2026 | 5989 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2023 | 137 | 0.050 |
Why?
| | Nucleotides | 1 | 2023 | 130 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2024 | 164 | 0.050 |
Why?
| | Azoxymethane | 1 | 2022 | 18 | 0.050 |
Why?
| | Patched-1 Receptor | 1 | 2022 | 14 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2022 | 93 | 0.050 |
Why?
| | Histones | 2 | 2019 | 663 | 0.040 |
Why?
| | Cell Death | 1 | 2023 | 383 | 0.040 |
Why?
| | Ligands | 1 | 2024 | 667 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2026 | 737 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 200 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 337 | 0.040 |
Why?
| | Antioxidants | 1 | 2023 | 549 | 0.040 |
Why?
| | Administration, Topical | 1 | 2020 | 153 | 0.040 |
Why?
| | Colon | 1 | 2022 | 308 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2018 | 2499 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 74 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 85 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 153 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 384 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 234 | 0.040 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 8 | 0.040 |
Why?
| | Humans | 8 | 2026 | 145491 | 0.040 |
Why?
| | Lipids | 1 | 2023 | 709 | 0.030 |
Why?
| | Wound Healing | 1 | 2021 | 355 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2017 | 16 | 0.030 |
Why?
| | Macrophages | 1 | 2026 | 1509 | 0.030 |
Why?
| | Keratitis | 1 | 2017 | 20 | 0.030 |
Why?
| | Blister | 1 | 2017 | 39 | 0.030 |
Why?
| | Doxycycline | 1 | 2017 | 62 | 0.030 |
Why?
| | Erythema | 1 | 2017 | 28 | 0.030 |
Why?
| | Androgens | 1 | 2018 | 178 | 0.030 |
Why?
| | Cadherins | 1 | 2018 | 200 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 505 | 0.030 |
Why?
| | Silymarin | 1 | 2017 | 147 | 0.030 |
Why?
| | Corneal Opacity | 1 | 2016 | 8 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1040 | 0.030 |
Why?
| | Edema | 1 | 2017 | 124 | 0.030 |
Why?
| | Rupture | 1 | 2016 | 91 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2016 | 161 | 0.030 |
Why?
| | Skin Absorption | 1 | 2015 | 14 | 0.030 |
Why?
| | Rad51 Recombinase | 1 | 2015 | 15 | 0.030 |
Why?
| | Eye | 1 | 2016 | 112 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 929 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 126 | 0.030 |
Why?
| | Diet | 1 | 2022 | 1280 | 0.030 |
Why?
| | Peptide Hydrolases | 1 | 2015 | 106 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2014 | 316 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 268 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 461 | 0.020 |
Why?
| | Blotting, Western | 1 | 2016 | 1162 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4127 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1439 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2022 | 4559 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2030 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1374 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1080 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 970 | 0.020 |
Why?
| | Protein Binding | 1 | 2015 | 2250 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3759 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7171 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5202 | 0.010 |
Why?
| | Female | 2 | 2022 | 78763 | 0.010 |
Why?
|
|
Kant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|